These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 4859626)

  • 21. Antibody response following customary use of MMR vaccine.
    Balfour HH; Edelman CK; Amren DP
    JAMA; 1984 Jun 22-29; 251(24):3223-4. PubMed ID: 6726993
    [No Abstract]   [Full Text] [Related]  

  • 22. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interruption of measles transmission in schoolchildren, 1995.
    Wkly Epidemiol Rec; 1995 Jul; 70(30):215-7. PubMed ID: 7669525
    [No Abstract]   [Full Text] [Related]  

  • 24. [Rubella screening in school girls using the radial hemolysis test and their vaccination with attenuated live vaccine of the RA23/3 strain].
    Strauss J; Benes C; Macátová I
    Z Gesamte Hyg; 1988 Oct; 34(10):589-91. PubMed ID: 3201803
    [No Abstract]   [Full Text] [Related]  

  • 25. The national measles and rubella campaign--one year on.
    Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
    [No Abstract]   [Full Text] [Related]  

  • 26. Present status of measles and rubella immunization in the United States: a medical progress report.
    Krugman S
    J Pediatr; 1971 Jan; 78(1):1-16. PubMed ID: 5539083
    [No Abstract]   [Full Text] [Related]  

  • 27. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WHO European Region's strategy for elimination of measles and congenital rubella infection.
    Hanon FX; Spika John J; Wassilak Steven S; Emiroglu N
    Euro Surveill; 2003 Jun; 8(6):129-30. PubMed ID: 12878802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of measles, mumps, and rubella immunization status using oral fluid samples.
    Thieme T; Piacentini S; Davidson S; Steingart K
    JAMA; 1994 Jul; 272(3):219-21. PubMed ID: 8022041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune status of children one to four years of age as determined by history and antibody measurement.
    Gold E; Fevrier A; Hatch MH; Herrmann KL; Jones WL; Krugman RD; Parkman PD
    N Engl J Med; 1973 Aug; 289(5):231-5. PubMed ID: 4351596
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccination with combined live measles and rubella vaccines.
    Ramos Alvarez M; Bessudo L
    Rev Invest Salud Publica; 1972; 32(2):110-5. PubMed ID: 4584450
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of measles-rubella vaccination for mothers in early puerperal phase.
    Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K
    Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles immunization: new recommendation.
    Krugman S
    JAMA; 1977 Jan; 237(4):366. PubMed ID: 576171
    [No Abstract]   [Full Text] [Related]  

  • 36. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunity to measles and rubella in women infected with human immunodeficiency virus.
    Clark RA; Dlamini G; Brandon W; Wisniewski T
    Clin Infect Dis; 1992 Oct; 15(4):739. PubMed ID: 1420696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.